| SC 13G | 2024-03-08 | JANUS HENDERSON GROUP PLC | Applied Therapeutics Inc. | 6,414,642 | 6.1% | EDGAR |
| SC 13D/A | 2024-03-05 | Shendelman Shoshana | Applied Therapeutics Inc. | 8,646,891 | 8.2% | EDGAR |
| SC 13G/A | 2024-02-22 | Propel Bio Management, LLC | Applied Therapeutics Inc. | 8,071,526 | 10.5% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Applied Therapeutics Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | ALEXANDRIA REAL ESTATE EQUITIES, INC. | Applied Therapeutics Inc. | 12,859,054 | 15.4% | EDGAR |
| SC 13G/A | 2024-02-14 | Venrock Healthcare Capital Partners III, L.P. | Applied Therapeutics Inc. | 7,877,817 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Alyeska Investment Group, L.P. | Applied Therapeutics Inc. | 7,715,197 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | ARMISTICE CAPITAL, LLC | Applied Therapeutics Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | PERCEPTIVE ADVISORS LLC | Applied Therapeutics Inc. | 4,580,249 | 5.9% | EDGAR |
| SC 13G | 2024-02-13 | Vestal Point Capital, LP | Applied Therapeutics Inc. | 4,155,000 | 5.4% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | Applied Therapeutics Inc. | 2,427,436 | 3.1% | EDGAR |
| SC 13G/A | 2024-02-06 | FRANKLIN RESOURCES INC | Applied Therapeutics Inc. | 7,793,912 | 10.0% | EDGAR |
| SC 13G/A | 2023-12-11 | FRANKLIN RESOURCES INC | Applied Therapeutics Inc. | 7,870,697 | 10.2% | EDGAR |
| SC 13G | 2023-12-06 | PERCEPTIVE ADVISORS LLC | Applied Therapeutics Inc. | 4,580,249 | 5.9% | EDGAR |
| SC 13D/A | 2023-11-13 | Shendelman Shoshana | Applied Therapeutics Inc. | 8,080,945 | 10.1% | EDGAR |
| SC 13G/A | 2023-05-10 | FRANKLIN RESOURCES INC | Applied Therapeutics Inc. | 7,946,732 | 16.5% | EDGAR |
| SC 13G | 2023-05-08 | Venrock Healthcare Capital Partners III, L.P. | Applied Therapeutics Inc. | 5,797,585 | 10.0% | EDGAR |
| SC 13G | 2023-05-02 | Propel Bio Management, LLC | Applied Therapeutics Inc. | 4,757,382 | 9.9% | EDGAR |
| SC 13D/A | 2023-04-28 | Shendelman Shoshana | Applied Therapeutics Inc. | 8,075,377 | 13.3% | EDGAR |
| SC 13G/A | 2023-03-31 | Propel Bio Partners L.P. | Applied Therapeutics Inc. | 1,234,519 | 2.6% | EDGAR |